ArticleHeliyon2024
Successful treatment of sepsis-induced cardiomyopathy with 36 hours refractory ventricular fibrillation: A case report.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the mechanisms of the NLRP3 inflammasome in sepsis‑induced cardiomyopathy and targeted therapeutic studies (Review).Molecular medicine reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-induced cardiomyopathy (SIC) is generally characterized by decreased cardiac ejection fraction (EF) reversibility, less cardiac response to fluid resuscitation and catecholamine, and rarely complicated with refractory ventricular fibrillation (RVF). Once RVF is induced, the mortality rate of sepsis patients will be greatly increased. In this case, we reported a 26-year-old female patient who was diagnosed sepsis-induced cardiomyopathy (SIC), presented with RVF for 36 hours. The patient was maintained by the mechanical circulatory support (MCS) devices and experienced twice defibrillation. Finally, the patient was discharged without intracardial thrombosis and severe craniocerebral complications. This case suggested that early application of MCS and appropriate frequency of defibrillation may help the prognosis of SIC with RVF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.